Estrella Immunopharma Inc. (ESLA NASDAQ) stock market data APIs
$0.8871
-0.02(-2.3%)
as of July 7, 2025
Try our APIs with
free plan!
Estrella Immunopharma Inc. Financial Data Overview
Price chart is built with
Anychart
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California.
Prev. Close
0.8871
Open
0.8662
High
0.944
Low
0.8585
52 wk Range
0.63-3.23
Market Cap
31 826 K
Shares Outstanding
36 166 K
EPS
-0.06
Beta
0.374
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Estrella Immunopharma Inc. data using free add-ons & libraries
Get Estrella Immunopharma Inc. Fundamental Data
Estrella Immunopharma Inc. Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-14
- EPS/Forecast: -0.11
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Estrella Immunopharma Inc. News
New
Estrella Immunopharma secures $3.35M in financing to advance clinical triall; shares up
* Estrella Immunopharma (NASDAQ:ESLA [https://seekingalpha.com/symbol/ESLA]) entered into a securities purchase agreement for a private investment in public equity financing, expected to raise ~$3.3...
Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances
The International Monetary Fund believes that most of the impact from tighter money policies has already affected the U.S. economy, with the rest expected this year. Despite worries about a recession,...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
